SC US (TTGP)’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
– Sell
-2,803
Closed -$29.7M – 16
2021
Q2
$29.7M Sell
2,803
-2,399
-46% -$20.1M 0.19% 12
2021
Q1
$37.5M Hold
5,202
– – 0.22% 10
2020
Q4
$28.9M Hold
5,202
– – 0.17% 11
2020
Q3
$52M Hold
5,202
– – 0.5% 9
2020
Q2
$48.2M Hold
5,202
– – 2.83% 4
2020
Q1
$47.5M Hold
5,202
– – 3.64% 5
2019
Q4
$58.4M Hold
5,202
– – 2.51% 8
2019
Q3
$25.9M Hold
5,202
– – 1.15% 9
2019
Q2
$44.2M Buy
+5,202
New +$31.1M 3.02% 8

Other funds holding IRLA

SC US (TTGP)'s IRLA Position: Q3 2021 in Review

SC US (TTGP) sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q3 2021, closing a stake of 2,803 shares — an estimated $29.7M sold.

SC US (TTGP) first reported a position in IRLA in Q2 2019 and held it in 9 quarters. The position peaked at $58.4M in Q4 2019. 126 funds tracked by Wall St. Rank hold IRLA as of Q3 2021.

  • SC US (TTGP) reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • SC US (TTGP) sold 2,803 IRulya Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $29.7M.
  • SC US (TTGP) first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and held it in 9 quarters.
  • SC US (TTGP)'s IRulya Therapeutics Inc. Common Stock position peaked at $58.4M in Q4 2019.
  • 126 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2021.

Based on SC US (TTGP)'s 13F filing for Q3 2021, filed 15 Nov 2021.